BioSpace News Archive

Toronto, Ontario--(Newsfile Corp. - January 8, 2021) - Relay Medical Corp. (CSE: RELA) (OTCQB: RYMDF) (FSE: EIY2) (“Relay” or the “Company”), is pleased to announce that further to its press release of December 18, 2020, the Company has completed the first tranche of its non-brokered private placement financing (the “Offering”) through the issuance of 25,375,000 units (each, a “Unit”) at a price of $0.20 per Unit for gross proceeds of $5,075,000.

BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that Jay M. Short , Ph.D., Chief Executive Officer, and Scott Smith , President, with participation by other BioAtla executives, will present at the 39 th Annual J.P. Mor

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter and full year 2020 financial results, as well as on its financial guidance for 2021, on Wednesday, February 10, 2021 at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please dial the fol

Curis, Inc. announced that on January 4, 2021, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 185,000 shares of Curis common stock to three new employees, with a grant date of January 4, 2021.

Fresenius Kabi USA is voluntarily recalling a single lot of Ketorolac Tromethamine Injection, USP, 30 mg/mL, 1 mL fill in a 2 mL amber vial to the user level due to the presence of particulate matter. Particulate matter was found in reserve sample vials. No adverse event reports have been received for the recalled lot, which was produced and sold in 2019. This press release features multimedia. View the full release

Recent milestones include first two FDA approvals at Vants launched by Roivant, positive clinical data at Dermavant, Aruvant, and Immunovant, and multiple computationally-designed protein degraders advanced into preclinical development

The global blood cell analyzer market depicts a highly competitive and expansive vendor landscape to exist, says Transparency Market Research on the basis of a recently published report.

The global non-surgical skin tightening market is projected to record an impressive CAGR during the forecast period, 2017 to 2022, according to Transparency Market Research’s newly published report.

Maruho Co., Ltd., based in Osaka, Japan, announced that its Board of Directors has named Atsushi Sugita Representative Director, President & CEO, effective December 18, 2020.

The global in-vitro diagnostics quality control market is prognosticated to grow notably in forthcoming years.